Barinthus Biotherapeutics plc.

BRNS

Barinthus Biotherapeutics plc.

BRNS

Insider Sentiment (TTM):

Last Purchase:2023-06-26Last Sale:2023-03-27Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:11,685Shares Outstanding:40,848,893Institutional Ownership Pct.:0.03%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Nonrelated Party	-	-	-	-	-	-	-	-	-	-	0	-
Related Party	-	-	-	-	-	-	-	-	-	-	0	-
Cash And Cash Equivalents At Carrying Value	59	66	70	74	86	99	111	106	118	130	142	160
Contract With Customer Asset Net Current	-	-	-	-	-	-	-	15	-	-	-	-
Restricted Cash Current	0	1	1	1	2	1	2	-	-	-	0	-
Deferred B Shares	-	-	-	-	-	-	-	-	-	-	0	0
Deferred C Shares	-	-	-	-	-	-	-	-	-	-	0	0
Assets
Assets Current
Prepaid Expense And Other Assets Current	2	4	5	6	8	6	6	8	10	8	10	7
Assets Of Disposal Group Including Discontinued Op…	-	-	-	0	0	-	-	-	-	-	-	-
Assets Current	63	73	78	87	100	110	126	135	132	143	157	171
Property Plant And Equipment Net	3	3	4	5	5	6	7	11	11	12	12	12
Intangible Assets Net Excluding Goodwill	13	14	14	15	20	21	22	23	24	24	25	26
Goodwill	-	-	-	-	-	-	0	12	12	12	12	12
Operating Lease Right Of Use Asset	2	2	2	2	3	4	4	7	7	7	8	7
Other Assets	1	1	1	1	1	1	1	1	1	1	1	1
Assets	82	92	98	109	130	142	160	189	187	199	215	230
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	0	1	2	1	2	3	3	1	2	5
Deferred Income Current	0	0	1	1	2	1	2	2	1	1	0	-
Operating Lease Liability Current	2	2	2	2	2	2	2	2	2	2	2	2
Liabilities Current	11	12	10	11	13	12	16	15	16	13	13	19
Liabilities Noncurrent
Operating Lease Liability Noncurrent	9	9	9	10	10	10	10	11	11	11	11	11
Business Combination Contingent Consideration Liab…	3	3	3	3	3	3	3	2	2	2	2	2
Other Liabilities Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Deferred Income Tax Liabilities Net	0	0	0	0	0	0	0	0	-	-	1	-
Liabilities	25	26	24	25	27	26	30	29	30	27	28	34
Stockholders Equity Inclu…
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	395	394	394	393	394	394	393	392	390	389	387	386
Retained Earnings Accumulated Deficit	-320	-310	-304	-293	-278	-257	-238	-217	-209	-192	-177	-159
Accumulated Other Comprehensive Income Loss Foreig…	-18	-19	-16	-16	-13	-21	-26	-16	-25	-25	-23	-31
Stockholders Equity	57	66	74	84	102	116	130	159	157	172	187	195
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities And Stockholders Equity	82	92	98	109	130	142	160	189	187	199	215	230
Deferred Shares.	-	-	-	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	41	41	41	41	40	40	40	40	39	39	39	39
Common Stock Shares Issued	41	41	41	41	40	40	40	40	39	39	39	39
Shares Outstanding	41	41	41	41	40	40	40	40	39	39	39	39

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	5.69%	1.85%	-14.46%	-	-	-	-	-	-	-	-	-
2025	9.09%	-7.47%	80.81%	-22.76%	-15.86%	-8.28%	-26.17%	-34.21%	-32.62%	-4.61%	3.50%	8.27%
2024	-15.14%	-40.09%	-38.59%	-4.71%	-14.49%	7.97%	-33.47%	-28.48%	-31.85%	-30.40%	-14.16%	-1.49%
2023	-	-	-	-6.85%	41.10%	66.21%	-3.08%	13.54%	-10.77%	28.16%	-4.69%	-18.78%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.54	6.05	7.77	8.04	7.89	9.18	8.03	8.93	8.46	11.15	12.45	9.21
Quick Ratio	5.33	5.70	7.28	7.45	7.29	8.65	7.63	8.39	7.85	10.53	11.67	8.86
Working Capital	51.85M	60.66M	67.77M	75.98M	87.69M	97.91M	110.09M	119.58M	116.29M	130.30M	144.31M	152.50M
Leverage & Debt
Debt to Equity	0.43	0.39	0.32	0.29	0.26	0.23	0.23	0.18	0.19	0.16	0.15	0.18
Interest Coverage TTM	-825.00	-1,098.63	-1,383.43	-1,647.60	-1,420.26	-1,326.96	-1,282.45	-1,345.17	-1,876.13	-1,983.60	-2,996.93	-4,242.48
Debt Ratio	0.30	0.28	0.24	0.23	0.21	0.19	0.19	0.15	0.16	0.14	0.13	0.15
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.09	0.09	0.08	0.07	0.00	0.00	0.00	0.16
Per Share Metrics
Diluted EPS TTM	-1.02	-1.28	-1.64	-1.87	-1.72	-1.62	-1.55	-1.47	-1.64	-1.82	-1.91	-2.00
Free Cash Flow Per Share TTM	-0.93	-0.89	-1.18	-0.39	-0.59	-0.81	-0.76	-1.58	-1.42	-1.63	-1.48	-1.27
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-512.35%	-478.70%	-454.07%	-431.34%	-	-23,755.69%	-10,463.09%	-226.47%
Net Profit Margin TTM	-	-	-	-	-463.87%	-435.85%	-408.00%	-386.98%	-	-21,184.43%	-9,157.98%	-196.35%
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-100.00%	-100.00%	-	4,381.74%	1,766.46%	-61.95%	-100.00%	-99.46%	-98.96%	2.86%
Net Income Growth (1Y)	-39.86%	-19.84%	8.77%	31.01%	8.69%	-7.79%	-16.85%	-25.01%	16.30%	358.44%	-1,474.90%	-773.08%
EPS Growth (1Y)	-40.61%	-20.98%	5.60%	27.01%	5.18%	-11.21%	-18.88%	-26.69%	14.42%	349.46%	-1,434.12%	-750.61%
Valuation Metrics
P/E TTM	-0.65	-0.44	-0.43	-0.67	-0.54	-0.60	-0.78	-0.81	-0.86	-1.30	-1.93	-1.54
P/B TTM	0.47	0.35	0.38	0.60	0.37	0.34	0.37	0.29	0.35	0.54	0.76	0.61
P/S TTM	-	-	-	-	2.51	2.62	3.18	3.13	-	276.29	176.62	3.03
Market Cap	26.96M	23.24M	28.37M	50.83M	37.52M	39.18M	47.53M	46.91M	54.66M	92.28M	141.65M	119.07M
Enterprise Value	-32.67M	-43.95M	-43.48M	-24.85M	-50.26M	-61.40M	-64.87M	-59.19M	-63.12M	-37.69M	-443.85K	-41.24M
Calculated Values
Free Cash Flow TTM	-37.97M	-36.48M	-48.02M	-16.06M	-23.65M	-32.61M	-29.83M	-62.40M	-55.31M	-63.09M	-56.64M	-48.82M
Net Debt	-59.63M	-67.19M	-71.85M	-75.67M	-87.78M	-100.58M	-112.40M	-106.10M	-117.77M	-129.97M	-142.09M	-160.31M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2023-06-26Purchase

Owner: Scheeren, Joseph

Title: -

Shares: 10,000

Price/Share: $2.44

Value: $24,400.00

Shares Owned: 23,000

Relationship: Director

Ownership: Direct

2023-05-25Purchase

Owner: Wright, Robin

Title: -

Shares: 13,750

Price/Share: $2.66

Value: $36,575.00

Shares Owned: 48,256

Relationship: Director

Ownership: Direct

2023-03-27Sale

Owner: Enright, William

Title: Chief Executive Officer

Shares: 15,000

Price/Share: $2.42

Value: $36,300.00

Shares Owned: 728,454

Relationship: Director,Officer

Ownership: Indirect

2022-08-25Sale

Owner: Griffiths, Graham

Title: Chief Business Officer

Shares: 10,000

Price/Share: $7.39

Value: $73,900.00

Shares Owned: 104,209

Relationship: Officer

Ownership: Direct

2022-08-25Sale

Owner: Ellis, Christopher

Title: Chief Operating Officer

Shares: 39,176

Price/Share: $6.38

Value: $249,942.88

Shares Owned: 75

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2023-06-26	Scheeren, Joseph	Director	-	Direct	Purchase	10,000	2.44	$24,400.00	23,000	4
2023-05-25	Wright, Robin	Director	-	Direct	Purchase	13,750	2.66	$36,575.00	48,256	4
2023-03-27	Enright, William	Director,Officer	Chief Executive Officer	Indirect	Sale	15,000	2.42	$36,300.00	728,454	4
2022-08-25	Griffiths, Graham	Officer	Chief Business Officer	Direct	Sale	10,000	7.39	$73,900.00	104,209	4
2022-08-25	Ellis, Christopher	Officer	Chief Operating Officer	Direct	Sale	39,176	6.38	$249,942.88	75	4
2022-08-18	Ellis, Christopher	Officer	Chief Operating Officer	Direct	Sale	2,175	4.84	$10,527.00	75	4
2022-08-17	Griffiths, Graham	Officer	Chief Business Officer	Direct	Sale	500	4.76	$2,380.00	114,209	4
2022-08-16	Griffiths, Graham	Officer	Chief Business Officer	Direct	Sale	1,220	4.82	$5,880.40	114,709	4
2022-08-16	Ellis, Christopher	Officer	Chief Operating Officer	Direct	Sale	2,200	4.78	$10,516.00	75	4
2022-08-12	Griffiths, Graham	Officer	Chief Business Officer	Direct	Sale	5,000	4.50	$22,500.00	118,329	4
2022-06-28	Ellis, Christopher	Officer	Chief Operating Officer	Direct	Sale	5	6.00	$30.00	75	4
2022-06-23	Griffiths, Graham	Officer	Chief Business Officer	Direct	Sale	8	5.28	$42.24	123,229	4
2022-04-01	Scheeren, Joseph	Director	-	Direct	Purchase	10,000	5.09	$50,900.00	13,000	4
2022-03-31	Hammacher, Alex	Director	-	Direct	Purchase	2,000	5.14	$10,280.00	3,000	4
2021-12-31	Hammacher, Alex	Director	-	Direct	Purchase	1,000	10.86	$10,860.00	1,000	4
2021-12-22	Wright, Robin	Director	-	Direct	Purchase	10,000	9.97	$99,700.00	34,506	4
2021-05-04	Wright, Robin	Director	-	Direct	Purchase	14,000	17.00	$238,000.00	24,506	4
2021-05-04	Dawes, Karen A	Director	-	Direct	Purchase	1,700	17.00	$28,900.00	1,700	4
2021-05-04	Phillips, Anne M.	Director	-	Direct	Purchase	3,000	17.00	$51,000.00	3,000	4
2021-05-04	Scheeren, Joseph	Director	-	Direct	Purchase	3,000	17.00	$51,000.00	3,000	4
2021-05-04	Ellis, Christopher	Officer	Chief Operating Officer	Direct	Purchase	75	17.00	$1,275.00	75	4
2021-05-04	Oxford, Sciences Innovati…	TenPercentOwner	-	Direct	Purchase	600,000	17.00	$10,200,000.00	8,797,770	4
2021-05-04	Griffiths, Graham	Officer	Chief Business Officer	Direct	Purchase	100	17.00	$1,700.00	100	4
2021-04-30	M&G, Investment Managemen…	TenPercentOwner	-	Indirect	Purchase	125,000	14.40	$1,800,000.00	1,088,597	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

0.03%

Inst. Shares: 11,685

Shares Outstanding: 40,848,893

2025-12-31

0.03%

Inst. Shares: 11,685

Shares Outstanding: 40,527,218

2024-12-31

0.00%

Inst. Shares: 75

Shares Outstanding: 39,348,240

2024-09-30

0.00%

Inst. Shares: 75

Shares Outstanding: 39,419,447

2024-06-30

0.00%

Inst. Shares: 75

Shares Outstanding: 39,041,111

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	11,685	40,848,893	0.03%
2025-12-31	11,685	40,527,218	0.03%
2024-12-31	75	39,348,240	0.00%
2024-09-30	75	39,419,447	0.00%
2024-06-30	75	39,041,111	0.00%
2024-03-31	75	38,773,482	0.00%
2023-12-31	75	38,386,491	0.00%
2023-09-30	9,562,426	38,533,833	24.82%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Barinthus Biotherapeutics plc. (BRNS) — SEC Financial Statements & Analysis

Barinthus Biotherapeutics plc. (BRNS) is a pharmaceutical preparations company, incorporated in X0. Barinthus Biotherapeutics plc. trades on Nasdaq as: BRNS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Barinthus Biotherapeutics plc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.43x, a Price-to-Sales (P/S) ratio of 2.51x (TTM), a Price-to-Book (P/B) ratio of 0.47x (TTM), at a market cap of $26.96M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.43x
P/S TTM: 2.51x
P/B TTM: 0.47x
Market Cap: $26.96M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Barinthus Biotherapeutics plc. in?

Barinthus Biotherapeutics plc. (BRNS) operates in the Pharmaceutical Preparations industry.

What is BRNS's market cap?

Barinthus Biotherapeutics plc. (BRNS) has a market capitalization of $26.96M as of 2026-06-30.

What exchange does BRNS trade on?

Barinthus Biotherapeutics plc. (BRNS) trades on the Nasdaq.

Where is Barinthus Biotherapeutics plc. incorporated?

Barinthus Biotherapeutics plc. is incorporated in United Kingdom.